Actavis plc
IndexS&P 500 P/E- EPS (ttm)-4.18 Insider Own0.10% Shs Outstand265.06M Perf Week-0.69%
Market Cap72.59B Forward P/E16.50 EPS next Y16.60 Insider Trans0.00% Shs Float264.10M Perf Month6.53%
Income-1046.00M PEG- EPS next Q3.56 Inst Own88.70% Short Float6.03% Perf Quarter14.87%
Sales11.78B P/S6.16 EPS this Y-793.40% Inst Trans0.29% Short Ratio5.28 Perf Half Y27.47%
Book/sh110.26 P/B2.48 EPS next Y21.67% ROA-3.10% Target Price309.22 Perf Year48.72%
Cash/sh1.28 P/C213.26 EPS next 5Y22.35% ROE-6.60% 52W Range179.11 - 285.09 Perf YTD6.40%
Dividend- P/FCF43.05 EPS past 5Y-35.20% ROI-3.00% 52W High-3.93% Beta0.28
Dividend %- Quick Ratio0.80 Sales past 5Y27.90% Gross Margin49.60% 52W Low52.91% ATR6.37
Employees19200 Current Ratio1.40 Sales Q/Q83.00% Oper. Margin-0.20% RSI (14)53.95 Volatility2.21% 2.22%
OptionableYes Debt/Eq0.53 EPS Q/Q-906.10% Profit Margin-8.10% Rel Volume0.73 Prev Close280.20
ShortableYes LT Debt/Eq0.52 EarningsFeb 18 BMO Payout- Avg Volume3.02M Price273.88
Recom1.60 SMA202.21% SMA503.74% SMA20018.20% Volume2,206,957 Change-2.26%
Jan-21-15Reiterated Deutsche Bank Buy $280 → $330
Jan-13-15Reiterated CRT Capital Buy $270 → $288
Nov-21-14Reiterated Argus Buy $285 → $310
Nov-20-14Reiterated RBC Capital Mkts Top Pick $291 → $323
Nov-18-14Reiterated UBS Buy $278 → $333
Nov-06-14Reiterated RBC Capital Mkts Top Pick $286 → $291
Sep-22-14Downgrade Barclays Overweight → Equal Weight $250 → $250
Aug-06-14Reiterated UBS Buy $237 → $254
Jul-02-14Reiterated CRT Capital Buy $245 → $275
Jun-27-14Initiated Canaccord Genuity Buy $275
May-12-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
May-01-14Reiterated CRT Capital Buy $230 → $245
Apr-28-14Reiterated National Alliance Securities Buy $246 → $259
Apr-17-14Initiated National Alliance Securities Buy $246
Feb-21-14Reiterated RBC Capital Mkts Outperform $240 → $249
Feb-19-14Reiterated UBS Buy $202 → $237
Feb-19-14Reiterated CRT Capital Buy $210 → $230
Feb-19-14Reiterated Barclays Overweight $230 → $250
Feb-03-14Reiterated RBC Capital Mkts Outperform $202 → $222
Feb-03-14Reiterated Barclays Overweight $190 → $230
Jan-28-15 06:30PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog Zacks
05:50PM  Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog Zacks
Jan-27-15 06:00PM  Actavis to Buy Auden Mckenzie, Boost Generic Portfolio - Analyst Blog Zacks
04:45PM  Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Zacks
03:20PM  Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Zacks
12:00PM  Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Zacks
11:20AM  Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog Zacks
06:16AM  Richter CEO Bogsch Sees Revenue Boost From Bayer Patch License at Bloomberg
Jan-26-15 09:41PM  Allergan sets up meeting to seek shareholder OK of Actavis acquisition at Los Angeles Times
05:30PM  Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC PR Newswire
05:30PM  Actavis Registration Statement for Pending Acquisition of Allergan Declared Effective by the SEC Business Wire
04:00PM  Supernus Files Oxtellar XR Patent Infringement Lawsuit Again - Analyst Blog Zacks
03:13PM  6 Big M&A Deals To Know About Today and What That Means For The Market Yahoo Finance Contributors
10:41AM  Actavis Buys Auden Mckenzie, Now UK's Largest Generics Firm at
08:15AM  Actavis to Buy Auden Mckenzie at The Wall Street Journal
07:30AM  Actavis to Acquire Auden Mckenzie for 306M GBP PR Newswire
Jan-25-15 09:22PM  Pfizers $33 Billion Cash Pile Has Everyone Guessing at Bloomberg
Jan-23-15 12:40PM  Will Abiomed (ABMD) Outshine Q3 Earnings Estimates? - Analyst Blog Zacks
11:30AM  Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog Zacks
01:28AM  Davos: Why M&A won't go away at CNBC
Jan-22-15 06:36PM  Top World Stocks Close In On Buy Points, New Highs at Investor's Business Daily
06:26PM  Thursday's Market Recap Yahoo Finance Contributors
Jan-21-15 06:03PM  Investment Bets On Antibiotics To Help Invigorate Investor Portfolios at Forbes
04:19PM  Stocks Grab Third Straight Gain; Baidu Nears Resistance at Investor's Business Daily
01:19PM  Stocks Hold Near Day's Highs; Actavis Retakes Buy Point at Investor's Business Daily
12:23PM  Hungry Actavis pauses to digest Allergan at Financial Times
12:09PM  Actavis and Valeant raise prospect of more pharma deals at Financial Times
11:40AM  Jim Cramer Sees Actavis Shares Going Higher, Possibly to $320 at TheStreet
09:55AM  Cramer's Stop Trading: ACT doesn't quit CNBC
06:00AM  This Giant Drug Firm Won't Invent Medicines. Investors Are Cheering at Forbes
Jan-20-15 04:30PM  Actavis/Gedeon Richter Present Schizophrenia Drug Data - Analyst Blog Zacks
03:06PM  Salix Pharma Reportedly Exploring Sale; Stock Up at Investor's Business Daily
12:57PM  The Woman Who Is Posting Some Of The Hedge Fund World's Best Returns at Forbes
02:00AM  Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia PR Newswire
Jan-17-15 09:00AM  Battered Hedge Fund Billionaire John Paulson Adds To Merger Bets at Forbes
Jan-15-15 02:12PM  3 Reasons To Be Bullish On Generic Drug Firm Akorn at Investor's Business Daily
Jan-14-15 04:17PM  Citadel Advisors decreases position in Apple Market Realist
09:30AM  Biopharma's challenges in 2015 CNBC
08:21AM  ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
08:17AM  Citadel Advisors adds position in Actavis Plc Market Realist
08:02AM  Meet 5 Top Medical Stocks Making Waves This Week at Investor's Business Daily
07:23AM  Three platinum stock picks for your portfolio CNBC
05:00AM  How an Obscure Tax Loophole Brought Down Obama's Treasury Nominee Bloomberg
Jan-13-15 08:17AM  Sass' top three portfolio plays CNBC
08:00AM  Actavis Launches U.S. Generic Specialty Injectable Portfolio PR Newswire
Jan-12-15 05:29PM  And Oil continues to fall... Yahoo Finance Blogs
04:23PM  Stocks Close Sharply Lower; Medicals Move On Announcements at Investor's Business Daily
01:52PM  Celgene Says Q4 Earnings Beat, Sees Currency Impact at Investor's Business Daily
12:38PM  Actavis CEO: Good can come from activists CNBC
09:44AM  Actavis expects profit to beat expectations at MarketWatch
09:29AM  Actavis Profit to Beat Expectations at The Wall Street Journal
08:46AM  ACTAVIS PLC Files SEC form 8-K, Results of Operations and Financial Condition EDGAR Online
08:30AM  Actavis Announces Exceptional Preliminary Fourth Quarter 2014 Performance PR Newswire
08:00AM  Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings PR Newswire
08:00AM  Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis Pending Acquisition of Allergan and Record Dates for Shareholder Meetings Business Wire
Jan-11-15 06:22PM  Shire to buy NPS for $5.2 billion at USA TODAY
Jan-08-15 06:06PM  Four Hot Growth Stocks To Put On Your Watch List at Investor's Business Daily
Jan-07-15 07:05AM  Bill Ackman: Valeant could have raised bid for Allergan CNBC
03:05AM  Appeals court leaves intact Alzheimer's drug order AP
Jan-06-15 06:17PM  Will Allergan Buy Help Actavis Extend Growth Streak? at Investor's Business Daily
03:54PM  Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA┬« IR PR Newswire
02:00AM  Actavis and Gedeon Richter Announce FDA Receipt of NDA Resubmission for Cariprazine PR Newswire
Jan-01-15 10:20AM  Glenview Capital raises position in Endo International Market Realist
07:00AM  Our Take on the Fourth Quarter Morningstar
Dec-31-14 02:20PM  Glenview Capital adds new position in 21st Century Fox Market Realist
08:20AM  Glenview Capital adds new position in Actavis Market Realist
08:02AM  These 5 Big Caps Saw Sales Surge Last Quarter at Investor's Business Daily
Dec-30-14 04:29PM  Glenview Capital starts new position in Realogy Holdings Market Realist
Dec-26-14 10:49AM  Story Stocks from
Dec-24-14 03:10PM  FDA denies approval for Actavis hypertension treatment Reuters
01:15PM  Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension PR Newswire
01:10PM  Another Eye-Popping Twist in Allergan Deal: the Bankers' Fees at The Wall Street Journal
12:05PM  The Bests and the Bloopers from the Year in Deals at The Wall Street Journal
08:24AM  Adamas' stock soars after dementia treatment approval at MarketWatch
08:02AM  Want Some Top-Performing Large-Cap Growth Funds? at Investor's Business Daily
08:00AM  Actavis and Adamas Announce FDA Approval of Namzaric, a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride PR Newswire
Dec-22-14 06:23PM  Actavis, Valeant Largely Avoid Gilead's Hepatitis Dive at Investor's Business Daily
09:24AM  Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer PR Newswire
09:00AM  Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference PR Newswire
06:33AM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre EDGAR Online
Dec-19-14 04:15PM  XYDALBA (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults PR Newswire
09:00AM  Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference PR Newswire
Dec-18-14 06:09PM  Baidu, Alibaba Among Top World Stocks Building Bases at Investor's Business Daily
11:54AM  Tetraphase Jumps As 'Superbug' Drug Scores In Trial at Investor's Business Daily
Dec-16-14 10:12PM  Few Allergan execs to keep top jobs in Actavis takeover at Los Angeles Times
06:11PM  Great Stocks: Valeant Pharmaceuticals Near Buy Point at Investor's Business Daily
10:28AM  Actavis Unveils Management Changes at The Wall Street Journal
10:11AM  Pharma Deal's Victor Now Must Execute at The Wall Street Journal
09:49AM  Activis to Replace Most Allergan Executives After Deal at Bloomberg
09:42AM  FDA Ruling Blocking Celebrex Generics Reversed in Win For Mylan at Bloomberg
07:30AM  Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition PR Newswire
07:06AM  Court Rules on Alzheimers Drug at The Wall Street Journal
07:06AM  Pharma Deals Victor Now Must Execute at The Wall Street Journal
Dec-15-14 06:47PM  Judge halts Alzheimer's drug swap until July AP
03:10PM  Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA┬« IR PR Newswire
09:27AM  Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015 at TheStreet
Dec-12-14 05:10PM  ACTAVIS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
02:20PM  Actavis Likely to Continue Selling Namenda IR Tablets Zacks
12:00PM  Chilton starts new position in Medtronic Market Realist
08:00AM  Chilton initiates new position in Actavis Market Realist
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.